1h
Hosted on MSNBridgeBio Oncology to Go Public in SPAC Deal Bringing $450 Million-Plus for Trio of Cancer DrugsClinical-stage BridgeBio Oncology Therapeutics, whose financial backers include Cormorant Asset Management, is going public ...
Explore the exciting world of BridgeBio Pharma(NASDAQ: BBIO) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and ...
BridgeBio Oncology Therapeutics (BBOT), a company advancing small molecule therapeutics targeting RAS and PI3Ka malignancies, ...
The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...
12h
GlobalData on MSNBridgeBio Oncology and Helix enter definitive merger agreementBridgeBio Oncology has entered into a merger agreement with Helix Acquisition Corp II to form a combined entity.
For a while, special purpose acquisition companies were biotech’s hot ticket to the public markets. | For a while, special ...
BridgeBio Oncology Therapeutics, which was spun out of BridgeBio Pharma (NASDAQ:BBIO) last year, has agreed to merge with ...
Prescription totals for Attruby, which is locked in a closely watched commercial battle with Pfizer’s tafamidis, have more ...
BofA raised the firm’s price target on BridgeBio (BBIO) to $46 from $45 and keeps a Buy rating on the shares after accounting for the updated ...
Long term debt management strategy will strengthen the balance sheet without increasing total liabilities - Refinancing term ...
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its price target lifted by Citigroup from $45.00 to $49.00 in a research ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results